In dry eye disease (DED), the normal functioning of the tear film is disrupted, resulting in troublesome ocular symptoms such as eye burning, and presenting with typical signs such as reduced tear production. Few drugs are approved in the U.S. market for managing DED; AbbVie’s (earlier Allergan) blockbuster Restasis enjoyed the status of the only therapy approved for this indication for more than a decade until the launch of Novartis’s Xiidra in 2016, the newer Restasis MultiDose formulation in 2017, and Sun Ophthalmics’ Cequa in 2019. In addition to these approved drugs, other pharmacotherapies, such as topical corticosteroids, are commonly prescribed to treat DED. This content provides manufacturers of current treatments, as well as those developing novel agents for DED, with real-world insights regarding recent trends in the use of drugs in this indication.
- What patient shares do key pharmacotherapies and brands garner by line of therapy in newly diagnosed DED patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DED patients?
- How have Restasis, Restasis MultiDose, and Xiidra been integrated into the treatment algorithm, and what is their source of business?
- What percentage of DED patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of DED patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with DED?
Geographies: United States
Real world data: Longitudinal patient-level claims data analysis
Key drugs covered: Restasis, Restasis MultiDose, Xiidra, corticosteroids (ophthalmic), antibiotics (oral and ophthalmic)
Key analysis provided:
Brand / therapy usage across longitudinal patient sample.
Newly diagnosed patient analysis.
Treatment initiation and progression.
Line of therapy analysis.
Combination therapy analysis.
Source of business for recently treated patients.
Persistency and compliance analysis.
Product-level patient flowcharts.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Dry Eye - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA Dry Eye Disease US May 2020
Author(s): Himanshu Jain, M.S. Pharm
Himanshu joined the CNS / ophthalmology team at Decision Resources Group in 2016. He has authored content for psychiatry and ophthalmology (retinal / nonretinal) indications, including schizophrenia, age-related macular degeneration, diabetic retinopathy / diabetic macular edema, dry eye disease, glaucoma, and uveitis.
Himanshu has more than ten years of experience working in market research and consulting firms, and has managed multiple market assessment projects, including bottom-up forecasts, across multiple therapy areas. He holds a M.S. degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.